SAN FRANCISCO--(BUSINESS WIRE)--Counsyl, a health technology company that offers DNA screening for diseases that can impact men, women and their children, today announced the appointment of Dr. James Goldberg as Chief Medical Officer. With more than 30 years of clinical experience and extensive expertise in reproductive genetics, Dr. Goldberg will lead Counsyl’s collaboration with the medical community, conceptualize and execute high-impact clinical studies, and help educate patients and physicians on the many benefits of screening.
“Dr. Goldberg is a pioneer in obstetrics and genetics, and we’re energized to have him join as our Chief Medical Officer. Dr. Goldberg has used Counsyl services extensively in his own practice and comes to us with an incredibly rich background,” said Ramji Srinivasan, co-founder and chief executive officer of Counsyl. “The landscape of the tools and tests that doctors can offer to patients is rapidly evolving. We had a strong need for an expert who could help build relationships with the medical community about what advancements in genetic screening mean for patient care. Dr. Goldberg will fill a key role on our team.”
Dr. Goldberg is board-certified in obstetrics and gynecology, maternal-fetal medicine, and medical genetics, and is a founding fellow of the American College of Medical Genetics. He was previously the director of the Reproductive Genetics Unit at the University of California, San Francisco and subsequently co-director of the Prenatal Diagnosis Center at California Pacific Medical Center and partner at San Francisco Perinatal Associates. Dr. Goldberg has also served as president of the Perinatal Quality Foundation and on the board of the Society for Maternal Fetal Medicine. He has published extensively in the area of prenatal diagnosis and has served on committees that establish national policy in obstetrical care. He has been repeatedly featured in “The Best Doctors in America” database.
Counsyl offers three main categories of screening, all of which require a doctor’s prescription. Counsyl’s Family Prep Screen looks at a couple’s DNA for serious genetic diseases that they can unknowingly pass on to their future children. With access to this information, couples can better prepare as they look to grow their family. Counsyl also offers an Inherited Cancer Screen, which analyzes two protective genes – BRCA1 and BRCA2 – and provides people with information about their cancer risk, and an Informed Pregnancy Screen that provides early insight into a baby’s development using non-invasive methods. Once patients receive their results, Counsyl makes it quick and easy to schedule an on-demand session with a genetic counselor. Patients with insurance pay between $150 and $300 on average for a Counsyl screen, depending on their insurance.
“I’ve used Counsyl’s services for some time and am thrilled at the opportunity to work alongside the Counsyl team in charting a new path for patient-centric health,” said Dr. Goldberg. “The sooner you know about genetic alterations that may lead to health challenges for you or your children, the more options become available. Counsyl’s work to make this actionable health information affordable, understandable and accessible to everyone is truly groundbreaking, and I look forward to furthering this mission in my new role.”
For more information on Counsyl, please visit www.counsyl.com
Counsyl is a health technology company that offers DNA screening for diseases that can impact men, women and their children. The Counsyl philosophy is simple: screen for diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.
The Counsyl team includes an incredible group of problem-solvers — top engineers, scientists, and designers — who are taking the lead on building the modern clinical laboratory. Scientific rigor, custom robotics, and software are at the heart of every Counsyl product, resulting in better, faster and more affordable screens that are broadly accessible. Beyond the laboratory, Counsyl offers doctors and patients a technology platform for results delivery in real time, with on-demand access to board-certified genetic counselors.
Counsyl has screened more than 350,000 patients and served over 6000 health care professionals in its CLIA-certified, CAP-accredited and NYS CLEP-permitted clinical laboratory. The company has raised a total of $102 million and is privately backed by Rosemont Seneca Technology Partners, Goldman Sachs Asset Management, Founders Fund, Felicis Ventures, David Drummond, and other high profile investors.